Emory University School of Medicine, Atlanta, GA 30322, USA.
Transpl Int. 2013 Jul;26(7):673-83. doi: 10.1111/tri.12100. Epub 2013 May 8.
Antibody therapy for induction is seldom used in liver transplantation in the United States, but continues to be used in approximately 10% of patients. The most commonly used antibody at the current time is basiliximab (Simulect, Novartis) and is used in adults with renal dysfunction at the time of liver transplantation with the intention of delaying introduction of calcineurin-inhibitors. In children, the same antibody is commonly used in order to reduce rates of acute rejection. Most patients, adult and pediatric, are treated with initially higher levels of tacrolimus rather than antibody induction.
在美国，肝移植中很少使用诱导抗体治疗，但仍有约 10%的患者在使用。目前最常用的抗体是巴利昔单抗（Simulect，诺华），用于肝移植时肾功能不全的成人，目的是延迟钙调神经磷酸酶抑制剂的应用。在儿童中，为了降低急性排斥反应的发生率，通常也会使用相同的抗体。大多数患者，包括成人和儿童，最初会接受更高剂量的他克莫司治疗，而不是抗体诱导治疗。
